Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | EBP | Q15125 | 3/20 | 0.65 |
| ▸ | DHCR7 | Q9UBM7 | 3/20 | 0.65 |
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | ESRRG | P62508 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | GBA1 | P04062 | 1/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23851093 | 1.00 | ESR1 (0.65) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL24322411 | 1.00 | ESR1 (0.65) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL24323673 | 0.89 | ESR1 (0.62) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL23852035 | 0.88 | ESR1 (0.60) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL24322242 | 0.88 | ESR1 (0.60) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL23852037 | 0.88 | ESR1 (0.60) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL6226404 | 0.83 | ESR1 (0.81) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL28507550 | 0.82 | ESR1 (0.92) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL6515775 | 0.81 | ESR1 (0.90) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL5321561 | 0.81 | ESR1 (0.90) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-24 | — | — | US | disclosed |
| EP-3883556-A2 | TGF? INHIBITOR AND PRODRUGS | Fundació Institut de Recerca Biomèdica IRB (Barcelona) (ES) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | TGFB1, TGFBR1, TGFBR2 | ESR1 2521/4885ESR2 876/4885MAPT 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.